低剂量替罗非班改善血管内取栓后急性缺血性卒中患者功能结局
结果显示替罗非班不增加症状性颅内出血风险,且与较低死亡率和较好长期功能独立相关。
要点
- 替罗非班不增加症状性颅内出血风险(11% vs 10%,P=0.808)。
- 替罗非班组死亡风险较低(23% vs 44%,P=0.005)。
- 替罗非班与长期功能独立改善相关(调整OR 4.37,95%CI 1.13-16.97,P=0.033)。
核心结论
- 在血管内取栓的急性缺血性卒中患者中,替罗非班不增加症状性颅内出血,可能降低死亡风险并改善长期功能独立。
主要发现
- 替罗非班组症状性颅内出血10例(11%),非替罗非班组9例(10%),差异无统计学意义(P=0.808)。
- 早期再闭塞替罗非班组4例(4.4%),非替罗非班组8例(8.9%),差异无统计学意义(P=0.370)。
- 替罗非班与长期功能独立相关(调整OR 4.37,95%CI 1.13-16.97,P=0.033)。
临床怎么用
- 对于接受血管内取栓的急性缺血性卒中患者,可考虑使用低剂量替罗非班以降低死亡风险并改善长期功能独立,但需进一步研究确定最佳方案。
局限性
- 本研究为单中心观察性研究,样本量有限,替罗非班预防早期再闭塞的疗效及最佳治疗协议尚需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Chinese patients largely experience acute ischemic stroke (AIS) because of large artery atherosclerosis rather than cardioembolism, and whether tirofiban is safe and effective in these patients treated with endovascular thrombectomy (ET) is unknown. This study evaluated the safety and efficacy of tirofiban in Chinese patients with AIS treated with ET. METHODS: This observational study is based on a single-center prospective registry study. Patients with AIS undergoing ET with second-generation stent retrievers from January 2013 to February 2017 were treated with ET alone or ET plus low dose of tirofiban. The primary outcome was symptomatic intracerebral hemorrhage (sICH). The secondary outcomes included rate of early reocclusion, any ICH, fatal ICH, and 3-month and long-term functional outcomes. RESULTS: One hundred eighty AIS subjects were included in the analysis, including 90 subjects treated with tirofiban and 90 subjects without tirofiban. Sixty-three subjects (35%) had any ICH, 19 of them (11%) were sICH, and 9 of them (5%) were fatal ICH. Ten subjects (11%) treated with tirofiban experienced sICH and 9 subjects (10%) not given tirofiban experienced sICH, not a significant difference (P=0.808). Early reocclusion happened in 4 of 90 subjects (4.4%) treated with tirofiban and 8 of 90 subjects (8.9%) not treated with tirofiban (P=0.370). One hundred sixty-one subjects (89%) completed long-term follow-up, subjects treated tirofiban were associated with lower odds of death (23% versus 44%, P=0.005) when compared with those who were not treated. Additionally, tirofiban was associated with better odds of long-term functional independence (adjusted odds ratio, 4.37; 95% confidence interval, 1.13-16.97; P=0.033). CONCLUSIONS: In patients with AIS undergoing ET, tirofiban is not associated with higher sICH, it seems to lead to lower odds of deaths and better odds of long-term functional independence. Further investigations are needed to determine the efficacy of tirofiban in preventing early reocclusion, the underlying mechanisms, and its optimal treatment protocol.
引用
- Zhao W, Che R, Shang S, et al. Low-Dose Tirofiban Improves Functional Outcome in Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy. Stroke. 2017. PMID: 29127270. doi:10.1161/STROKEAHA.117.019193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。